| 描述信息 |
The anti-inflammatory and vasoprotective properties of high-density lipoprotein cholesterol (HDL-C) make it best known in cardiovascular disease. Here, our cohort and meta-analysis shown patients with inflammatory bowel disease (IBD) had dramatically declined HDL-C. Besides, HDL-C level was restored by anti-TNFα therapy and acted as a predictor for patients outcome. Interestingly, the inverse association of HDL-C level with patients inflammatory status was confirmed not only in IBD but also in other systemic and organ-specific autoimmune and chronic inflammatory diseases. Increasing HDL-C by cholesteryl ester transfer protein inhibitors (CETPi) evacetrapib before or even after the onset of experimental colitis allayed disease severity via transcriptional repressor ATF3 dependent anti-inflammatory reprogramming of macrophages. Together, those results uncovered an important role of HDL-C in IBD and indicated the potential pharmacological effects of CETPi for future IBD therapy. |
